Camlin Fine Sciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
CAMLINFINE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.2 pts more than Nifty Microcap 250 and 7.7 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Camlin Fine Sciences reported FY26 standalone revenue of ₹83,791.82 lakh, down 5.5% from ₹88,649.13 lakh in FY25, with standalone loss before tax of ₹5,409.22 lakh (improved from ₹12,343.05 lakh loss in FY25). On consolidated basis, revenue grew 5.8% to ₹172,330.81 lakh from ₹162,868.75 lakh, primarily due to the Vinpai acquisition completed in November 2025. However, consolidated profit after tax from continuing operations declined significantly to ₹3,153.10 lakh from ₹6,508.90 lakh in FY25. Key items include: exceptional items of ₹405.82 lakh (acquisition costs), ₹763.43 lakh loss from fire at CFS Do Brasil, and ₹222.17 lakh impact from new labour codes. CFS Europe SpA was liquidated in March 2026, resulting in a gain of ₹10,290.51 lakh from derecognition of net liabilities. Auditors issued unmodified opinions on both standalone and consolidated financial statements.
The mixed results show revenue growth on consolidated basis but significant PAT decline of ~51.5% from continuing operations, indicating margin pressure despite the Vinpai acquisition. The standalone revenue decline and persistent losses may concern investors, though improved performance versus prior year loss is a positive.